Abstract:In the current issue of EBioMedicine, Jin et al. demonstrated a humanized mouse (hu-mouse) model in which a functional human immune system was established and genetically-matched (autologous) to primary acute B-lymphoblastic leukemia (B-ALL) in severe immunodeficient NSG mice [[1]Jin C.H. Xia J. Rafiq S. Huang X. Hu Z. Zhou X. et al.Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.EBioMedicine. 2019; 20: 2-3Google Scholar]. Using this hu-mouse model, the authors generated CD19-targeted chimeric antigen receptor (CAR) T cells from human autologous mature T cells and tested the efficacy of CAR-T therapy against primary B-ALL. Anti-CD19 CAR-T therapy has made a significant impact on the clinical prognosis of patients with relapsed or refractory B-cell lymphoma [[2]Schuster S.J. CD19-directed CAR T cells gain traction.Lancet Oncol. 2018 Jan; 30 (PubMed PMID: 30518503): 2-3Summary Full Text Full Text PDF Scopus (15) Google Scholar,[3]Havard R. Stephens D.M. Anti-CD19 chimeric antigen receptor T cell therapies: harnessing the power of the immune system to fight diffuse large b cell lymphoma.Curr Hematol Malig Rep. 2018 Dec; 13 (PubMed PMID: 30362020): 534-542Crossref PubMed Scopus (13) Google Scholar]. Based on results of the ZUMA-1 trial and subsequently the JULIET trial [[4]Neelapu S.S. Locke F.L. Bartlett N.L. Lekakis L.J. Miklos D.B. Jacobson C.A. et al.Axicabtagene ciloleucel CAR T-Cell therapy in refractory large b-cell lymphoma.N Engl J Med. 2017 Dec 28; 377 (PubMed PMID: 29226797. Pubmed Central PMCID: 5882485): 2531-2544Crossref PubMed Scopus (2811) Google Scholar,[5]Schuster S.J. Bishop M.R. Tam C.S. Waller E.K. Borchmann P. JP McGuirk et al.Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma.N Engl J Med. 2019 Jan 3; 380 (PubMed PMID: 30501490): 45-56Crossref PubMed Scopus (1786) Google Scholar], the US Food and Drug Administration and the European Medicines Agency approved two anti-CD19 CAR-T products, with a CD28 or 4-1BB co-stimulatory domain, to treat pediatric or young adult B-cell precursor B-ALL in 2017, and then adults with relapsed or refractory diffuse large B-cell lymphoma in early 2018. Although these landmark clinical trials showed that anti-CD19 CAR-T therapy induced a consistent and durable response against B-cell malignances, approximately half of the patients in these studies failed to respond or acquired resistance [[4]Neelapu S.S. Locke F.L. Bartlett N.L. Lekakis L.J. Miklos D.B. Jacobson C.A. et al.Axicabtagene ciloleucel CAR T-Cell therapy in refractory large b-cell lymphoma.N Engl J Med. 2017 Dec 28; 377 (PubMed PMID: 29226797. Pubmed Central PMCID: 5882485): 2531-2544Crossref PubMed Scopus (2811) Google Scholar,[5]Schuster S.J. Bishop M.R. Tam C.S. Waller E.K. Borchmann P. JP McGuirk et al.Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma.N Engl J Med. 2019 Jan 3; 380 (PubMed PMID: 30501490): 45-56Crossref PubMed Scopus (1786) Google Scholar]. Among the suspected mechanisms of resistance to therapy, two convincing models proposed involve loss of CD19 and/or gain of expression of PD-L1. Furthermore, toxicities and side effects are also associated with CAR-T therapy, including cytokine release syndrome (CRS), neurologic toxicity and B-cell aplasia, which also limit the therapeutic potential [[6]Mahadeo K.M. Khazal S.J. Abdel-Azim H. Fitzgerald J.C. Taraseviciute A. Bollard C.M. et al.Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.Nat Rev Clin Oncol. 2017 Sep 15; 17 (PubMed PMID: 30082906): 632Google Scholar]. Therefore understanding the mechanisms by which resistance occurs and toxicities/side effects develop are highly warranted to further potentiate the success of anti-CD19 CAR-T therapy for treatment of B-cell malignances. Given that clinical trials have their own limitations to restrain in depth mechanistic studies in patients, the antitumor activity of CAR-engineered human T cells are primarily evaluated through in vitro assays or in immunodeficient mice engrafted with only human tumor cell lines. Although other studies using mouse models can reveal mechanistic insight in depth, these studies test murine CAR-T constructs on mouse T cells in response to mouse tumors. More recently, patient-derived xenograft (PDX) models have been created by grafting patient-derived cancer cells in immunodeficient mice. PDX models make it possible to directly assess human immune responses to human primary cancer cells, which recapitulate the clinical scenario with human cancers and immunotherapy [[7]Byrne A.T. Alferez D.G. Amant F. Annibali D. Arribas J. Biankin A.V. et al.Interrogating open issues in cancer medicine with patient-derived xenografts.Nat Rev Cancer. 2017 Sep 15; 17 (PubMed PMID: 28912576): 632Crossref PubMed Scopus (0) Google Scholar]. A PDX model was also used in evaluating the therapeutic efficacy of CAR T cells in human B-ALL. However, PDX models are typically established in immunodeficient mice and most of them involve allogeneic and/or xenogeneic immune responses that are obviously different from cancer patients. A group of investigators led by Yang and Sykes have made substantial effort to create humanized mouse models in which immunodeficient mice are fully reconstituted with human hematopoietic and immune systems [[8]Kalscheuer H. Danzl N. Onoe T. Faust T. Winchester R. Goland R. et al.A model for personalized in vivo analysis of human immune responsiveness.Sci Transl Med. 2012 Mar 14; 4 (PubMed PMID: 22422991. Pubmed Central PMCID: 3697150): 125ra30Crossref PubMed Scopus (94) Google Scholar]. Using these humanized mice, the Yang group has established numerous models that simulate human diseases or conditions, including a spontaneous human B-ALL model [[9]Xia J. Hu Z. Yoshihara S. Li Y. Jin C.H. Tan S. et al.Modeling human leukemia immunotherapy in humanized mice.EBioMedicine. 2016 Aug; 10 (PubMed PMID: 27394641. Pubmed Central PMCID: 5006579): 101-108Summary Full Text Full Text PDF PubMed Scopus (19) Google Scholar]. The current work by the same group utilized this human B-ALL model to evaluate the efficacy of anti-CD19 CAR-T therapy [[1]Jin C.H. Xia J. Rafiq S. Huang X. Hu Z. Zhou X. et al.Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.EBioMedicine. 2019; 20: 2-3Google Scholar]. There are several unique features in this model over previously published models: 1) the recipient hu-mice have a functional human hematopoietic and immune system; 2) autologous primary B-ALL is driven by a patient-derived fusion MLL-AF9 oncogene; 3) anti-CD19 CAR-expressing human T cells are also derived by mature human T cells from the same individual; 4) the human mature T cells as a source of CAR T cells are developed in the human thymus engrafted in murine host. These features offer many advantages of this unique model including permitting the evaluation of antitumor responses in immunocompetent hosts, testing human CAR-T constructs against human primary malignance, and avoiding allogeneic responses and anti-mouse xeno-antigens. These advantages make this model highly valuable for mechanistic and preclinical studies of anti-CD19 CAR T-cell immunotherapy. In fact, the current study demonstrates the efficacy of anti-CD19 CAR-T therapy, positive correlation of CAR-T survival and expansion with B-ALL regression, and causative relationship between proinflammatory cytokines and CRS. Given this proof-of-principle study, such hu-mouse models can be established to evaluate efficacy of various CAR-T cells in the treatment of relevant hematologic malignances and to study underlying mechanisms of resistance and toxicity. While presenting many advantages, this hu-mouse model is not identical to a human host. It is obvious that non-hematopoietic tissues are mouse origin that may interfere anti-tumor responses, although the concern is mitigated in the situation of hematologic malignances. A specific limitation in evaluating CAR-T therapy using this hu-mouse model may lay in toxicity studies, as IL-6 was below the detectable level in mouse sera [[1]Jin C.H. Xia J. Rafiq S. Huang X. Hu Z. Zhou X. et al.Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.EBioMedicine. 2019; 20: 2-3Google Scholar] similar to another published study using non-humanized NSG mice [[10]Singh N. Hofmann T.J. Gershenson Z. Levine B.L. Grupp S.A. Teachey D.T. et al.Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.Cytotherapy. 2017 Jul; 19 (PubMed PMID: 28506444): 867-880Summary Full Text Full Text PDF PubMed Scopus (93) Google Scholar]. The results are in sharp contrast to those from clinical trials where IL-6 has been shown to be a primary driving force for CRS. As discussed by the authors, using human cytokine-transgenic SGM3 mice that produce human SCF, GM-CSF and IL-3 might correct the defect, which remains to be investigated and confirmed. Technically, one should keep in mind that the procedure to establish such a hu-mouse model is rather convoluted. In conclusion, Jin et al. provide a preclinical mouse model that represents a close recapitulation of the human host in evaluating CAR-T therapy against hematologic malignancies to compensate the limitation of clinical trials. However, such a hu-mouse model is not identical to the human host and thus certain limitations remain. The authors declare no conflicts of interest. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemiaThese results provide a proof-of-principle that this novel preclinical model has the potential to be used to model human CAR T cell therapy and facilitate the design of new CARs with improved antitumor activity. Full-Text PDF Open Access

Abstract 4020: Donor-dependent anti-tumoral efficacy of human CD19 CAR T cells in a leukemic xenograft mouse model

Abstract 4002: Investigating CAR-T cell efficacy and activation in the disseminated NALM6-luc human B-cell acute lymphoblastic leukemia model

Abstract 1435: Utilization of CLDN18.2 syngeneic mouse models to study chimeric antigen receptor T cells in immunocompetent mice

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy

Abstract 2835: Chimeric antigen receptor (CAR) T-cell generation for therapeutic testing in the disseminated NALM6 human B-cell acute lymphoblastic leukemia mouse model

Abstract 5342: Evaluation of autologous and allogeneic T cell-based therapies in ex-vivo and in-vivo xenograft tumor models

Abstract PO1-26-05: Animal Study Compares CAR T cell Exhaustion & Ability to Kill Low Antigen expressing breast cancer cells among three CAR constructs including one with 1XX mutations

Abstract 5510: Preclinical study of allogeneic CD19-CAR-DNT cells as an off-the-shelf immunotherapy drug for NHL

Abstract 7239: Eradication of B cell lymphoma in a mouse model through in vivo transduction of T cells with an aCD19-CAR utilizing a CD3-targeted lentiviral vector

Abstract 3850: Modeling individual variability in CD19 CAR-T therapy: An in vivo study with PBMC-humanized mice

Abstract 4014: Humanized mouse model to assess PBMC donor derived autologous CD19 CAR Ts for efficacy against Raji tumors and related cytokine release

Modelling CAR-T Therapy in Humanized Mice.

Abstract 3198: Fully human CD20 and CD19 dual-targeting CAR-T cells mediate long-term remissions and protection from tumor rechallenge in vivo

Abstract 4018: An innovative in vivo model for CAR-T cell therapy development: Tolerability and efficacy evaluation of CD19-targeting CAR-T cells on human lymphoma using the chicken CAM assay

Abstract 5254: The “off-the-shelf ”CD19-CAR-Vδ1T cells demonstrated an enhanced therapeutic effect on B-cell malignancy models

Modeling Anti-Cd19 CAR T Cell Therapy in Humanized Mice with Human Immunity and Autologous Leukemia.

Abstract 581: bbT369, a dual-targeted and CBLB gene-edited autologous CART product, demonstrates anti-lymphoma activity in preclinical mouse models

Abstract 4010: Assessing impacts of tumor burden and CAR-T cell dosage on the toxicity and efficacy profile of CD19 CAR-T therapy in a PBMC-humanized mouse model

Abstract A011: Modeling the coevolution of native and CAR T-cells in large B cell lymphoma reveals a potential biomarker for response to therapy

Abstract 697: Enhanced tumor control and survival in solid tumor models following combined low dose radiotherapy and T cell therapy

Abstract 2216: Combinational Strategy Targeting B Cell Malignancy Using Ipsc Engineered CAR-NK (FT596) and CAR-T Cell (FT819) Platforms with Therapeutic Antibody to Achieve an Effective Deep and Durable Response